BMS Grows Its Lung Cancer Portfolio With ‘Best-In-Class’ Augtyro Approval
Drug Addresses 1%-2% Of NSCLC Patients
Bristol Myers Squibb won US FDA approval for Augtyro (repotrectinib), from its $4.1bn Turning Point acquisition last year, in the treatment of ROS1-positive non-small cell lung cancer (NSCLC).
You may also be interested in...
AstraZeneca’s Truqap and Evive’s Ryzneuta bring FDA center for drugs’ 2023 novel agent total to 51, while biologics center already sits on a record-breaking 14 novel approvals.
Bristol Myers Squibb will add Krazati to its oncology portfolio by buying Mirati Therapeutics in a deal worth up to $5.8bn, but needs to smooth out the so-far bumpy progress of the KRAS-targeting agent and achieve success in immunotherapy combinations.
Daily notebook from the J.P. Morgan Healthcare Conference: Turbulent weather matches sentiment about the year ahead, with investors looking for reassurance on the IRA, deal-making and growth strategy from big pharma. Updates from J&J, Biogen, BMS, Merck and more.